Deal notes
Closing has not been confirmed in the reviewed sources. This record does not establish that funding was received.
Transaction overview
01PMV Pharmaceuticals, Inc. announced a $50.8M underwritten public offering at $1.21 per share. TD Securities (USA) LLC acted as underwriter for the financing.
- Financing type
- Underwritten Public Offering
- Announcement date
- Aug 31, 2026
- Pricing date
- Aug 31, 2026
- Closing date
- —
- Filing date
- Sep 2, 2026
- Status
- Priced
- Market cap before announcement
- $65.1M
- Prior closing price
- $1.22
- Raise as % of market cap
- 78%
Market data · FMP
- Historical market cap
- $65,132,028
- Market date
- Aug 28, 2026
- Closing price
- $1.22
- Latest reported shares outstanding
- 53,331,766
- Latest reported float shares
- 48,896,034
- Share-data date
- Sep 29, 2026
Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Sep 30, 2026.
Financial Modeling Prep ↗Financing terms
02Equity
- Common shares issued
- 22,055,000
- Price per share
- $1.21
- Pre-funded warrants
- 19,900,000
- Pre-financing shares disclosed in filing
- —
- Shares outstanding after financing
- —
Investor warrants
- Warrant shares
- 41,955,000
- Cash exercise price
- $1.21
- Term
- Five years from issuance; immediately exercisable
- Initial exercisability
- —
- Beneficial ownership limits
- —
View disclosed legal provisions
Cashless exercise: —
Anti-dilution: In addition, beginning on the date of our initial public announcement of the decision by the U.S. Food and Drug Administration, or FDA, regarding the acceptance for review of our New Drug Application, or NDA, for rezatapopt for the treatment of patients with platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation, or the NDA Acceptance Announcement, the exercise price of the common stock warrants will be reduced to the greater of (i) 33% of the initial exercise price of the common stock warrants and (ii) the lesser of (x) the then exercise price and (y) the volume weighted average price of our common stock for the five trading day period beginning on the trading day following the NDA Acceptance Announcement, referred to as the Reset Exercise Price, if such Reset Exercise Price is less than the initial exercise price. If the exercise price of the common stock warrants is reduced to the Reset Exercise Price, the number of shares of common stock issuable pursuant to the common stock warrant shall be increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price to the Reset Exercise Price, shall be equal to the aggregate exercise price immediately prior to the date of the NDA Acceptance Announcement. See “ Description of Securities .” To the extent that the NDA Acceptance Announcement relates to a positive decision of the FDA to accept the NDA, then during the period beginning on the 30th calendar day following the date of the NDA Acceptance Announcement and ending on the 60th calendar day thereafter, we may require the holders of common stock warrants to exercise up to 50% of their common stock warrants for cash, or the Mandatory Exercise. Any common stock warrant which has not been exercised pursuant to the Mandatory Exercise shall become null and void and the rights of the holder of the common stock warrant to exercise such common stock warrant shall lapse.
Fees & transaction economics
03- Placement agent / underwriting fee
- 6%
- Agent fee amount
- $3.0M
- Management fee
- —
- Other offering expenses (estimated)
- $705,280
- Net proceeds (estimated)
- $47.0M
- Net proceeds as % of gross
- 92.5%
Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.
Transaction participants
04Source documents
05SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.
Filing evidence & original calculations
1.21
combined public offering price of each share of common stock and accompanying warrant is $1.21Original source ↗
6
Underwriting discounts and commissions (1) $ 0.07260 $ 0.07260 $ 3,045,933Original source ↗
Five years from issuance; immediately exercisable
are immediately exercisable from the date of issuance and will expire five years from the date of issuanceOriginal source ↗
In addition, beginning on the date of our initial public announcement of the decision by the U.S. Food and Drug Administration, or FDA, regarding the acceptance for review of our New Drug Application, or NDA, for rezatapopt for the treatment of patients with platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation, or the NDA Acceptance Announcement, the exercise price of the common stock warrants will be reduced to the greater of (i) 33% of the initial exercise price of the common stock warrants and (ii) the lesser of (x) the then exercise price and (y) the volume weighted average price of our common stock for the five trading day period beginning on the trading day following the NDA Acceptance Announcement, referred to as the Reset Exercise Price, if such Reset Exercise Price is less than the initial exercise price. If the exercise price of the common stock warrants is reduced to the Reset Exercise Price, the number of shares of common stock issuable pursuant to the common stock warrant shall be increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price to the Reset Exercise Price, shall be equal to the aggregate exercise price immediately prior to the date of the NDA Acceptance Announcement. See “ Description of Securities .” To the extent that the NDA Acceptance Announcement relates to a positive decision of the FDA to accept the NDA, then during the period beginning on the 30th calendar day following the date of the NDA Acceptance Announcement and ending on the 60th calendar day thereafter, we may require the holders of common stock warrants to exercise up to 50% of their common stock warrants for cash, or the Mandatory Exercise. Any common stock warrant which has not been exercised pursuant to the Mandatory Exercise shall become null and void and the rights of the holder of the common stock warrant to exercise such common stock warrant shall lapse.
In addition, beginning on the date of our initial public announcement of the decision by the U.S. Food and Drug Administration, or FDA, regarding the acceptance for review of our New Drug Application, or NDA, for rezatapopt for the treatment of patients with platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation, or the NDA Acceptance Announcement, the exercise price of the common stock warrants will be reduced to the greater of (i) 33% of the initial exercise price of the common stock warrants and (ii) the lesser of (x) the then exercise price and (y) the volume weighted average price of our common stock for the five trading day period beginning on the trading day following the NDA Acceptance Announcement, referred to as the Reset Exercise Price, if such Reset Exercise Price is less than the initial exercise price. If the exercise price of the common stock warrants is reduced to the Reset Exercise Price, the number of shares of common stock issuable pursuant to the common stock warrant shall be increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price to the Reset Exercise Price, shall be equal to the aggregate exercise price immediately prior to the date of the NDA Acceptance Announcement. See “ Description of Securities .” To the extent that the NDA Acceptance Announcement relates to a positive decision of the FDA to accept the NDA, then during the period beginning on the 30th calendar day following the date of the NDA Acceptance Announcement and ending on the 60th calendar day thereafter, we may require the holders of common stock warrants to exercise up to 50% of their common stock warrants for cash, or the Mandatory Exercise. Any common stock warrant which has not been exercised pursuant to the Mandatory Exercise shall become null and void and the rights of the holder of the common stock warrant to exercise such common stock warrant shall lapse.Original source ↗
47000000
approximately $47.0 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.Original source ↗
705280
total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $705,280Original source ↗
FMP reported market cap; as of 2026-08-28.
{"provider": "FMP", "symbol": "PMVP", "date": "2026-08-28", "marketCap": 65132028}Original source ↗